Abbott Laboratories Scores High with 62% Guru Rating

Abbott Laboratories achieves a score of 62% based on the Growth Investor strategy, highlighting potential growth despite some weaknesses. The report indicates strong earnings performance, but critics point to revenue growth discrepancies.

Date: 01-01-2025

AI Rating: 5

Earnings Per Share (EPS): The report indicates that Abbott Laboratories is experiencing positive EPS growth for the current quarter, as well as a pass in the current quarter EPS growth being greater than the prior three quarters. However, there are concerns as it fails to meet the criteria for EPS growth being greater than the historical growth rate, which suggests some volatility.

Revenue Growth: The report notes a significant point of concern with revenue growth being insufficient in relation to EPS growth, leading to a failure in this category. This can indicate challenges the company may face in maintaining healthy revenue streams compared to its earnings.

Profit Margins and Net Income: While specific profit margin metrics are not provided, the overall positive rating indicates reasonable valuations, which can suggest stable profit margins. However, further insights into net income specifically are lacking.

Overall Assessment: Abbott Laboratories scores a 62% under the Growth Investor strategy, with several aspects exhibiting strength, such as sales growth and positive trends in earnings persistence in recent quarters. Yet, the ratings reveal vulnerabilities in revenue growth and earnings consistency, which could raise concerns among potential investors. The mixed signals result in a nuanced perspective on the stock's future potential, necessitating careful analysis for investment decisions.

Stocks: ABT